Heart failure & cardiomyopathiesCohort study
Early Reduction of Pulmonary Artery Pressures Is Associated With Improved Mortality Among Medicare Beneficiaries With Heart Failure
- Retrospective cohort study
- Medicare claims linkage
Authors' conclusion
Among Medicare beneficiaries, CardioMEMS-guided management was associated with a reduction in PAD. Achieving acceptable PAD within 90 days of implant was associated with better survival.
Study context
- Population
- Medicare beneficiaries with HF implanted with the CardioMEMS sensor, 2017–2022cohort A
- Participants
- 9,579 beneficiaries
- Exposure
- Acceptable PAD vs Elevated PAD
- Outcome
- Mortality
- Follow-up
- 2 years
Main finding
2-year mortality by baseline PAD (cohort A)
Hazard ratio
0.68
95% CI 0.62–0.73
P < 0.001
By group
Elevated PAD
64.1%
Acceptable PAD vs Elevated PAD
HR 0.68 (95% CI 0.62–0.73); P < 0.001
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | Improved PAD | Persistently elevated PAD | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| Mortality by 90-day PAD trajectory (cohort B) · mortality | 24.0% | 76.0% | 0.72 (0.64–0.81) | P < 0.001 | |
| ΔPAD | −6.5 ± 4.3 mm Hg | −1.6 ± 4.3 mm Hg | |||
| 0.512Hazard ratio (log scale) |
- Mortality by 90-day PAD trajectory (cohort B): 63.3% elevated at baseline in cohort B; percentages are of those
Predictors of improved PAD
- Lower baseline PAD and no history of COPD or atrial arrhythmia associated with higher odds of improved PAD
Original publication
Early Reduction of Pulmonary Artery Pressures Is Associated With Improved Mortality Among Medicare Beneficiaries With Heart Failure. JACC Heart Fail. Published 13 August 2025. doi:10.1016/j.jchf.2025.102589
Summarised from the published abstract; every number is checked against it